Intellia Therapeutics shares are trading higher after the company announced long-term data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002.
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics shares are trading higher following the announcement of positive long-term data from the Phase 1 portion of their ongoing Phase 1/2 study of NTLA-2002.
June 03, 2024 | 11:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intellia Therapeutics shares are experiencing an upward trend due to the release of favorable long-term data from the Phase 1 study of NTLA-2002.
The positive long-term data from the Phase 1 study of NTLA-2002 is a significant milestone for Intellia Therapeutics, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100